This is a $28,098,860.50 Cost No Fee Definitive Contract awarded to Duke University by the National Institute of Allergy and Infectious Diseases (NIAID) for the NIAID Virology Quality Assurance (VQA) program. The contract has no set-aside designation. Under this contract, Duke University, a prominent private research university, will provide various research, laboratory, and quality assurance services to support NIAID's VQA program, which conducts medical research in areas such as virology and...
This is a $6,178,859.14 federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Duke University. The contract is for a "NONHUMAN PRIMATE CORE VIROLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENT". This is a definitive, cost-no-fee contract with a period of performance through December 14, 2024. The contract was awarded on December 22, 2017 and does not have a set-aside...
The National Cancer Institute (NCI) awarded a $10,586.28 firm fixed-price purchase order contract to Duke University to provide viral load assays to evaluate the levels of virus in macaques enrolled in vaccine studies. The contract has a completion date of July 7, 2025, and was awarded on July 8, 2024. Duke University's Office of Research Administration Division will be the prime contractor, and there is no set-aside designation for this award. This contract aligns with Duke's expertise in...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, awarded a $19,829,599.29 definitive cost-no-fee contract to Duke University for a Nonhuman Primate Core Humoral Immunology Laboratory to support AIDS vaccine research and development. The contract has a period of performance through March 29, 2025 and does not have a set-aside designation. Duke University's Office of Research Administration Division is the prime contractor for this award, which appears to be...
This is a federal contract award to Duke University by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH). The contract, valued at $10,236,804.91, is a Definitive Contract with a Cost Plus Fixed Fee pricing type. The contract does not have a set-aside designation. The contract is described as "TAS::75 0885::TAS", which likely refers to the task or service area, though the specific details are not provided. The...
This is a $2,361,452.65 federal contract award to Duke University, a private non-profit university, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). The contract is for a Phase 1 Clinical Trial Unit to develop therapeutics against infectious diseases. It is a delivery order placed under the Therapeutics Against Infectious Diseases Phase 1 indefinite delivery, indefinite quantity (IDIQ) contract. The contract has no...
This is a federal contract award to Duke University, a private university, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). The contract is part of the Vaccine and Treatment Evaluation Units (VTEU) program, which supports clinical research on vaccines and treatments for infectious diseases. The specific award is for Task B1C1 under contract HHSN272201300017I, with a ceiling value of $1,154,053.22. The award date was...
This $7,752,063.96 federal contract award to Duke University's Office of Research Administration Division is a delivery order issued under the Vaccine and Treatment Evaluation Units (VTEU) indefinite delivery, indefinite quantity (IDIQ) contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The award has a period of performance ending on July 12, 2024 and is for vaccine and treatment evaluation work, which aligns with the...
This federal contract award to Duke University was issued by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH), a civilian agency. The $13,368,236.91 definitive contract is for an "IMMUNOLOGY QUALITY ASSESSMENT PROGRAM" and does not have a set-aside designation. Duke University's Office of Research Administration Division is the prime contractor, and the contract has a period of performance ending on September...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, has awarded a $21,659,151.36 definitive cost-no-fee contract to Duke University to support the "ADVANCED DEVELOPMENT OF A NEUTRALIZING ANTIBODY VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES." This contract, which does not have a set-aside designation, will run through September 18, 2026. Duke University's Office of Research Administration Division will serve as the prime contractor on this...